Bioelectronic implants provide a versatile platform for diagnosis, therapeutics as well as basic research but require invasive surgery. As a part of the parent proposal, we are developing a paradigm shift: the ‘Circulatronics’ technology, wherein ultra-small bioelectronic devices target desired regions in the body for sensing and treatment, without the need for surgery. We are leveraging our work in ultra-scalable and record-low power nanoelectronics, which can lead to beyond-Silicon dimensional scalability to create sub-cellular sized and highly energy-efficient nanoelectronic devices. Moreover, we are building on our research in novel van der Waals heterostructures employing heterogeneous material systems enabled by atomically thin 2D materials to accomplish advanced electronic functionalities. Furthermore, we are exploring different surface functionalization and synthetic biology techniques to achieve the required targeting. This supplement will extend our technology to Alzheimer’s disease (AD). Current AD therapies only provide marginal symptomatic benefits due to inability to achieve early intervention and as irreversible neuron loss occurs after cognitive impairment. Pathological neuroinflammation, tau and amyloid-β (Aβ) aggregations, which are hallmarks of AD, start in small brain regions. We will leverage our technology of wireless subcellular sized nanoelectronics to target these pathological sites associated with AD for highly precise therapeutics. Our technology can provide the advantages of early-stage intervention which can be instrumental to slow down and even prevent development of AD. The proposed supplementary work is well within the scope of the parent award and will lead to future R01-funded research on novel AD therapeutics.